KEY TAKEAWAYS
- The LIST observational study aimed to characterize patient and treatment attributes, assess effectiveness, evaluate safety, and analyze rechallenge outcomes in the real-world setting through the LIST study of NSCLC.
- The results demonstrated nivolumab’s effectiveness and safety for immunotherapy-naive cancer patients, even after past checkpoint inhibitor complications.
Non-small cell lung cancer (NSCLC) treatment underwent significant transformation following the approval of the first immunotherapy agent (IO) in 2015, marking a pivotal shift in therapeutic approaches.
Benoît GODBERT and his research group spearheaded the study that aimed to delineate patient and treatment characteristics, assess effectiveness, evaluate safety, and analyze rechallenge outcomes.
The Lung Initiative on Sequence Therapy (LIST) study is an ongoing prospective observational investigation focusing on patients with advanced NSCLC undergoing nivolumab treatment following one prior chemotherapy-based regimen, either alone or combined with immune checkpoint inhibitors (IO). Patient cohorts include Cohort 1 (IO-naïve patients), Cohort 2 (IO-experienced patients discontinuing for non-IO-toxicity reasons), and Cohort 3 (IO-experienced patients discontinuing due to IO-toxicity). Descriptive interim analyses, conducted with a follow-up duration of ≥6 months, are presented.
About 428 patients were enrolled in the LIST study across 99 centers, distributed among cohorts 1, 2, and 3, with 278, 128, and 22 patients, respectively. Baseline characteristics reflected advanced NSCLC demographics. At 6 months, overall survival(OS) rates were 70.0% [95% CI 64.2–75.1%], 61.1% [51.6–69.3%], and 61.2% [37.1–78.4%] for cohorts 1, 2, and 3, respectively. Progression-free survival rates were 33.4% [27.6–39.2%], 25.1% [17.2–33.8%], and 51.0% [28.1–70.0%].
Current/former smokers and patients with tumor PD-L1 expression exhibited improved outcomes. Adverse events(AEs) occurred in 86%, 78%, and 73% of patients, with treatment-related grade 3/4 AEs in 11%, 5%, and 18% for cohorts 1, 2, and 3, respectively.
The interim results from the LIST study indicated that nivolumab’s activity and safety for immune checkpoint inhibitor-naïve patients in real-world clinical practice align with the findings from the registrational CheckMate 017/057 trials. Moreover, the study revealed promising outcomes for nivolumab rechallenge in patients with prior immune checkpoint inhibitor discontinuation, even in cases involving immune-related toxicity. The research is sponsored by Bristol-Myers Squibb.
Source: https://cslide.ctimeetingtech.com/immuno23hybrid/attendee/confcal/show/session/34
Clinical Trial: https://clinicaltrials.gov/study/NCT04500535
Godbert B.’’LIST (Lung Initiative on Sequence Therapy), a real-world study of nivolumab for advanced NSCLC in France: first effectiveness, safety, and IO-rechallenge results.’’ Presented at ESMO I-O 2023, Geneva, Singapore (Presentation Number 70P)
